FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults

Q: How long will it take to read this news story?

The story "FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults" has 760 words across 34 sentences, which will take approximately 4 - 7 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults" was covered 3 days ago by CNBC, a news publisher based in United States.

Q: How trustworthy is 'CNBC' news outlet?

CNBC is a fully independent (privately-owned) news outlet established in 2005 that covers mostly economy and business news. The outlet is headquartered in United States and publishes an average of 0 news stories per day. It's most recent story was published 1 days ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #9227384</li><li>URL: https://beamstart.com/news/fda-grants-full-approval-to-16850250474154</li></ul>

CNBC Logo CNBC 3d ago

FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults - CNBC

Quick Summary:

Pfizer and the FDA view Paxlovid as an important complementary tool to vaccination that can help high-risk Americans manage their Covid infections.

The FDA's latest decision means there is now extensive clinical data indicating Paxlovid is safe and effective.

The treatment consists of two medications: nirmatrelvir, which blocks a key enzyme that the Covid virus needs to replicate, and ritonavir, which boosts the first medication's ability to fight the infection.